Effect of Ezetimibe on Oxidized Low-density Lipoprotein (LDL) Cholesterol

Effect of Ezetimibe on Oxidized LDL Cholesterol

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01008345

Enrollment

100

Registered

2009-11-05

Start date

2008-09-30

Completion date

2009-06-30

Last updated

2009-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Diabetes

Brief summary

Randomized study. Patients with coronary artery disease equivalent will be randomized to receive atorvastatin 40 mg/day + placebo vs. atorvastatin 40 mg/day + ezetimibe 40 mg/day. Oxidized LDL cholesterol will be measured at baseline and after 8 weeks of treatment. Hypothesis is that ezetimibe will lower oxidized LDL

Interventions

DRUGezetimibe

Patients will receive 10 mg/day of ezetimibe for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

21 Years to 80 Years

Healthy volunteers

Inclusion criteria

* CAD or CAD equivalent

Exclusion criteria

* Prior CABG or PCI within 3 months Prior use of ezetimibe within 3 months Receiving atorvastatin 40 mg/day or 80 mg/day or any dose of rosuvastatin CHF NYHA stage \>2 Creatinin clearance \< 30 ml/min

Design outcomes

Primary

Measure	Time frame
level of oxidized LDL cholesterol at end of study	8 weeks of treatment

Secondary

Measure	Time frame
small dense LDL level	8 weeks of treatment

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026